Therapy and monitoring of heparin-induced thrombocytopenia type II in critically ill patients during continuous venovenous hemodiafiltration: Comparison of aPTT and ecarin clotting time for monitoring of r-hirudin therapy

Journal of Intensive Care Medicine

Volumn 17, Issue 1, 2002, Pages 34-40

  Muhl, Elke ^a   Siemens, Hans Joachim ^a   Kujath, Peter ^a   Bruch, Hans Peter ^a  

^a UNIVERSITY OF LÜBECK   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

HEPARIN; LEPIRUDIN; RECOMBINANT HIRUDIN;

ACUTE KIDNEY FAILURE; ADULT; AGED; BLOOD CLOTTING TIME; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG MONITORING; FEMALE; HEMODIALYSIS; HUMAN; KIDNEY BLOOD FLOW; LIVER CIRRHOSIS; MALE; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; REVIEW; SEPSIS; THROMBOCYTE COUNT; THROMBOCYTOPENIA; THROMBOEMBOLISM;

EID: 0036157705     PISSN: 08850666     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1525-1489.2002.17003.x     Document Type: Review

References (39)

1. Bleeding after intermittent or continuous r-hirudin during CVVH
2. Continuous haemofiltration with r-hirudin (lepirudin) as anticoagulant in a patient with heparin induced thrombocytopenia (HIT II)
3. Monitoring anticoagulant therapy by activated thromboplastin time: Hirudin assessment. An evaluation of native blood and plasma assays
4. The development of hirudin as an antithrombotic drug
5. The pharmacology of recombinant hirudin, a new anticoagulant
6. Pharmacokinetics of recombinant hirudin in hemodialyzed endstage renal failure patients
7. Hirudin elimination by hemofiltration: A comparative in vitro study of different membranes
8. Elimination von rekombinantem hirudin aus der blutzirkulation mittels hämofiltration
9. In vitro study of r-hirudin permeability through membranes of different haemodialyzers
10. Anticoagulation with r-hirudin in regular haemodialysis with heparin-induced thrombocytopenia (HIT II)
11. Pharmacokinetics of continuous renal replacement therapy
12. Individualized drug dosage in patients treated with continuous hemofiltration
13. The clinical usefulness of the platelet aggregation test for the diagnosis of heparin-induced thrombocytopenia
14. A rapid and sensitive test for diagnosing heparin-associated thrombocytopenia
15. Heparin-induced thrombocytopenia: New insights into the impacts of the Fc-gamma-RIIa-R-H-131 polymorphism
16. Monitoring of r-hirudin anticoagulation during cardiopulmonary bypass-assessment of whole blood ecarin clotting time
17. Immunologic response to recombinant hirudin in HIT type II patients during long-term treatment
18. Generation of anti-hirudin antibodies in heparin-induced thrombocytopenic patients treated with r-hirudin
19. Elimination of recombinant hirudin by modified ultrafiltration during simulated cardiopulmonary bypass: Assessment of different filter systems
20. Recombinant hirudin (lepirudin) as anticoagulant in intensive care patients treated with continuous hemodialysis
21. Recombinant hirudin (lepirudin) provides safe and effective anticoagulation in patients with heparin-induced thrombocytopenia: A prospective study
22. Lepirudin (recombinant hirudin) for parenteral anticoagulation in patients with heparin-induced thrombocytopenia
23. A new therapeutic option by subcutaneous recombinant hirudin in patients with heparin-induced thrombocytopenia type II: A pilot study
24. Quantitative determination of hirudin in blood and body fluids
25. Follow-up of the treatment by direct thrombin inhibitors: Activated partial thromboplastin time or ecarin clotting time
26. Coagulation laboratory testing in patients treated with argatroban
27. The pharmacokinetics and pharmacodynamics of argatroban: Effects of age, gender, and hepatic or renal dysfunction
28. Clinical experience of argatroban for anticoagulation in cardiovascular surgery
29. Sustained antithrombotic activity of hirudin after its plasma clearance: Comparison with heparin
30. Heparin-induced thrombocytopenia with thromboembolic complications: Meta-analysis of 2 prospective trials to assess the value of parenteral treatment with lepirudin and its therapeutic aPTT range
31. Heparin-induced thrombocytopenia
32. Heparin-induced thrombocytopenia as the cause of persistent bleeding after pacemaker implantation
33. Failure of current strategies in the prevention of thrombosis in patients with heparin-induced thrombocytopenia: A clinician's perspective
34. Failure of early cessation of heparin as treatment for heparin-induced thrombocytopenia
35. Diagnosis and therapeutic strategies of white clot syndrome
36. Heparin-induced immune thrombocytopenia
37. Heparin-induced thrombocytopenia
38. Heparin-induced thrombocytopenia (HIT): An overview of 230 patients treated with orgaran (Org 10172)
39. Efficacy and safety of danaparoid sodium (Org 10172) in critically ill patients with heparin-associated thrombocytopenia